drugset / Trial / NCT05168202
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 alone and in combination with antineoplastic agents in participants with relapsed or refractory acute myeloid leukemia and relapsed or refractory and treatment-naive higher risk melodysplastic syndromes.
Timeline
- Start
- 2022-01-19
- Primary completion
- 2024-07-30
- Completion
- 2024-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANZURSTOBART | Monoclonal antibody | — | — |
| Background | Azacitidine | Other / unclassified | — | — |
| Background | Venetoclax | Small molecule | — | — |